0.77
-3.14%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Euroapi
Its shares trade on Euronext Paris under the ticker EAPI.PA. It has been listed since 6 May 2022. In the fiscal year to 31 December 2025, it reported revenue of €848.2m and a net loss of €211.2m. At that date it held total assets of €1.30bn and shareholders' equity of €788.0m.
EUROAPI SA operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2022-05-06. The firm is engaged in the development, manufacture and supply of active-ingredient solutions to its healthcare partners. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates (morphine, codeine, thebaine, etc. ), analgesics, etc. The firm also provides technologies and develops molecules through it’s Contract Development and Manufacturing Organization (CDMO). It’s CDMO services include Tides, Prostaglandins, Particle Engineering, Microbial Fermentation, Small Molecules Synthesis, Steroids and Hormones and Opiates & Controlled Substances. The company has production sites located in France, the United Kingdom, Germany, Italy and Hungary.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 6 May 2022
- Employees
- 3,449
- Website
- euroapi.com/en ↗
Leadership
Pay as last reported
- Mr. Emmanuel BlinNon-Executive Independent Chairman of the Board€92,603
- Mr. David SeignolleChief Executive Officer€33,908
- Mr. Olivier FalutChief Financial Officer
- Mr. Jean-Yves CaminadeNon-Executive Director - Representative of Bpifrance Investissement
- Mr. Olivier KlaricNon-Executive Director - Representative of Sanofi Aventis Participations
- Ms. Geraldine LeveauNon-Executive Director
- Ms. Marie-Isabelle PenetNon-Executive Director - Representative of Employees
- Mr. Kevin RodierNon-Executive Director - Representative of Employees
- Ms. Elizabeth BastoniNon-Executive Independent Director€152,609
- Ms. Cecile DussartNon-Executive Independent Director€75,000
- Ms. Claire GirautNon-Executive Independent Director€85,000
- Mr. Mattias PerjosNon-Executive Independent Director€70,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Operates as a manufacturer and supplier of active pharmaceutical ingredient solutions for healthcare companies.
- Offers a diverse range of products including vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids, and hormones.
- Has production sites in multiple European countries including France, the United Kingdom, Germany, Italy, and Hungary.
Weaknesses
- The company's CDMO services include specific technologies but no additional details on their competitive advantage are provided.
- The source description is treated as untrusted facts and not to be followed.
- No information on financial performance or market share is provided.
Opportunities
- Expansion of CDMO services such as Tides, Prostaglandins, and Particle Engineering could attract more healthcare partners.
- Growth in demand for active pharmaceutical ingredients in the healthcare sector may benefit the company.
- Potential for leveraging production sites across Europe to enhance supply chain efficiency.
Threats
- The company's reliance on specific product lines like opiates and controlled substances may pose regulatory risks.
- The untrusted source description indicates potential inaccuracies in the provided information.
- Competition in the pharmaceutical manufacturing sector could impact market position.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.